Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility.

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

Precision Biosciences (NASDAQ:DTIL) is a biotech company with a proprietary gene-editing platform - ARCUS - 15 years in the making, and a promising genome editing endonuclease ...

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet to recognize the positive updates.

Precision BioSciences, a clinical stage gene editing company, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team.

DURHAM – Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...